| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -1.7 | -1.7 |
| Net income | -1.7 | -1.7 |
| EPS (diluted, $ a share) | $-0.59 | $-0.98 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +25.7% |
|---|
10-Q filed with the SEC, NASDAQ: CDIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cardio Diagnostics Holdings, Inc.: key numbers
- Share price
- $1.79Close, Nov 16
- Market cap
- $5.3M
- Shares outstanding
- 2.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cardio Diagnostics Holdings, Inc.
All →Cardio Diagnostics Holdings Shareholder Meeting
Cardio Diagnostics Holdings held its 2026 Annual Meeting of Stockholders on September 18, 2026, where shareholders elected seven directors and ratified Prager Metis CPAs LLC as the independent auditor. Additionally, stockholders approved the potential future issuance of common stock exceeding 20% of outstanding shares in non-public transactions, as required by Nasdaq Listing Rule 5635(d).